Gamamabs Pharma;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);Université de Montpellier;Institut Regional du Cancer de Montpellier - Val d'Aurelle
发明人:
申请号：
EP15305695.7
公开号：
EP3091033A1
申请日:
2015.05.06
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody comprising (a) a heavy chain wherein the variable domain comprises: a H-CDR1 having a sequence set forth as SEQ ID NO: 2； a H-CDR2 having a sequence set forth as SEQ ID NO: 3；and a H-CDR3 having a sequence set forth as SEQ ID NO: 4； and (b) a light chain wherein the variable domain comprises at least a CDR having a sequence chosen from the group consisting of SEQ ID NO: 6 as L-CDR1, SEQ ID NO: 7 as L-CDR2 and SEQ ID NO: 8 as L-CDR3； said antibody having a human constant region； and less than 65 % of the glycan structures carried by the glycosylation site of the antibody comprise a fucose molecule.A nucleic acid sequence encoding it, as well as a host cell, an immunoconjugate comprising it, a pharmaceutical composition comprising it as well as their pharmaceutical use are also considered.
